Know Cancer

or
forgot password

Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women


Phase 2
15 Years
39 Years
Not Enrolling
Female
Obesity

Thank you

Trial Information

Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women


In a randomized clinical trial study, 80 obese women with BMI≥30, oligomenorrhae, hirsutism
and presence of > 12 ovarian follicles (2-10mm diameter), were evaluated. In metformin group
, metformin was administered for patients 1500 mg daily for three months. In orlistate
group, patients used orlistat tablets (120 mg, 3 times a day) for three months. BMI, serum
LH and FSH levels, serum triglyceride and cholesterol levels and also patients' ovulation
was compared before and after treatment.


Inclusion Criteria:



- BMI>= 30

- PCOS

Exclusion Criteria:

- Drug use during last three months

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Outcome Measure:

Body Mass Index (BMI)

Outcome Time Frame:

3 months

Safety Issue:

Yes

Principal Investigator

Abbas Aflatoonian, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Research and Clinical center for Infertility

Authority:

Iran: Ministry of Health

Study ID:

616

NCT ID:

NCT01003483

Start Date:

November 2008

Completion Date:

October 2009

Related Keywords:

  • Obesity
  • metformin
  • orlistat
  • pcos
  • obese
  • Obesity
  • Polycystic Ovary Syndrome

Name

Location